Lord, Abbett & Co
RIGL icon

Lord, Abbett & Co’s Rigel Pharmaceuticals RIGL Stock Holding History

Lord, Abbett & Co’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-440,983
Closed -$13.2M – 617
2022
Q1 		$13.2M Buy
440,983
+7,722
+2% +$209K 0.04% 414
2021
Q4 		$11.5M Sell
433,261
-4,209
-1% -$127K 0.03% 466
2021
Q3 		$15.9M Sell
437,470
-5,832
-1% -$230K 0.04% 446
2021
Q2 		$19.2M Sell
443,302
-42,303
-9% -$1.6M 0.05% 426
2021
Q1 		$16.6M Buy
+485,605
New +$19.2M 0.04% 437

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lord, Abbett & Co's RIGL Position: Q2 2022 in Review

Lord, Abbett & Co sold out of Rigel Pharmaceuticals (RIGL) in Q2 2022, closing a stake of 440,983 shares — an estimated $13.2M sold.

Lord, Abbett & Co first reported a position in RIGL in Q1 2021 and held it in 5 quarters. The position peaked at $19.2M in Q2 2021. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2022.

  • Lord, Abbett & Co reported no remaining Rigel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 440,983 Rigel Pharmaceuticals shares in Q2 2022, an estimated $13.2M.
  • Lord, Abbett & Co first reported a position in Rigel Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Lord, Abbett & Co's Rigel Pharmaceuticals position peaked at $19.2M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2022.

Based on Lord, Abbett & Co's 13F filing for Q2 2022, filed 12 Aug 2022.